A comprehensive strategy based on ultra‐high performance liquid chromatography with diode array detector fingerprinting and multi‐component ultra‐performance liquid chromatography with tandem mass spectrometry technology for quality control of Jiawei Huoxiang Zhengqi Pill

Jiawei Huoxiang Zhengqi Pill (JHZP) is a commonly used Chinese patent medicine for the clinical treatment of headache, dizziness, chest tightness as well as abdominal distension, and pain caused by wind‐cold flu. In this study, a comprehensive strategy combining ultra‐high performance liquid chromatography with diode array detector (UHPLC‐DAD) fingerprinting and multi‐component quantitative analysis was established and validated for quality evaluation of JHZP. A total of 49 characteristic common peaks were selected in a chromatographic fingerprinting study to assess the similarity of 15 batches of JHZP. Furthermore, 109 compounds were identified or preliminarily identified from JHZP by coupling with an advanced hybrid linear ion trap‐Orbitrap mass spectrometer. For quantification, the optimized ultra‐performance liquid chromatography with tandem mass spectrometry (UPLC‐MS/MS) method was employed for the simultaneous determination of 13 target compounds within 12 min. The sensitivity, precision, reproducibility, and accuracy of the method were satisfactory. This validated UPLC‐MS/MS method was successfully applied to analyzing 15 batches of JHZP. The proposed comprehensive strategy combining UHPLC‐DAD fingerprinting and multi‐component UPLC‐MS/MS analysis proved to be highly efficient, accurate, and reliable for the quality evaluation of JHZP, which can be considered as a reference for the overall quality evaluation of other Chinese herbal formulations.